5 March 2013-WTO TRIPS Council-Intervention of India on Intellectual Property and Innovation: Small and medium Sized Enterprises

On 5 March 2013, the Government of India delivered the following statement at the TRIPS Council on agenda item 13, Intellectual Property and Innovation: Small and Medium-Sized Enterprises, a standalone item tabled by Chile, Chinese Taipei, the Republic of Korea and the United States of America.

We thank the delegations of Chinese Taipei, Korea, the United States and others for tabling an agenda item on “Intellectual Property and Innovation: Small and medium Sized Enterprises” which we understand is a standalone item.

Continue Reading

Uncategorized

KEI on Medicines Patent Pool license (and MoU) with ViiV Healthcare

KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013

FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).

The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.

Continue Reading

Uncategorized

EU and US push WIPO negotiations against human rights, for restrictions on exceptions

WIPO is spending five days in a special session to work on the text for a treaty on copyright exceptions for persons who are blind or have other disabilities.

KEI has obtained a copy of the latest version as of Friday morning, which is attached below.

The first four days have been consumed with highly technical but important debates of the international rules for copyright exceptions. The US and the EU are demanding that all sorts of language be put into the treaty referring to a three step test to restrict the use of exceptions.

Continue Reading

Uncategorized

Comments on the the Bayer appeal of the compulsory license on Nexavar patents, February 17, 2013

These are KEI’s February 17, 2013 comments on the the Bayer appeal of the compulsory license on Nexavar patents.


Comments on the the Bayer appeal of the compulsory license on Nexavar patents.

February 17, 2013

The dispute is Bayer Corporation v Natco Pharma Limited, and is being heardbefore the Intellectual Property Appellate Board At Chennai (O.R.A. no. 35/PT/2012).

Continue Reading

Uncategorized

Why do US and EU trade negotiators hate the Berne Copyright Limitations and Exceptions?

For the past year, a treaty on copyright exceptions for persons who are blind or have other disabilities has been hung up on demands by the European Union to insert provocative language on the so called “three step test” in copyright into the treaty. The Trans Pacific Partnership Agreement is in the middle of a similar dispute, with the US pushing language that would place the three step test on top of all copyright limitations and exceptions, including those set out a particular cases in the Berne Convention. Continue Reading

Uncategorized

KEI’s 2013 Special 301 Comments

On Friday, 8 February 2013, KEI filed comments to USTR on the 2013 Special 301 Review. The comments request support for an extension of the transition period for least-developed countries, issues regarding compulsory licenses, patent linkage, exclusive rights over test data, and standards of patentability. With regard to copyright, KEI submitted comments covering issues of technological protection measures and DMCA-style legislation on notice-and-takedown procedures. KEI also made comments regarding the enforcement of intellectual property rights.

Continue Reading

Uncategorized